Efficacy and long-term outcome of gastritis therapy in cheetahs (Acinonyx jubatus)

Scott B. Citino, Linda Munson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A prospective clinical trial evaluating efficacy and long-term outcome of treatments for lymphoplasmacytic gastritis in cheetahs (Acinonyx jubatus) was conducted. The study evaluated efficacy of 11 different antibiotic and antiinflammatory treatment protocols in 32 cheetahs (19 male, 13 female) for reducing gastric inflammation and Helicobacter colonization and monitored the course of disease through histologic grading of gastric biopsies. All cheetahs were biopsied up to 1 wk before treatment and then rebiopsied within 1 mo after treatment. Most animals were reassigned to a second treatment regimen within 6 mo. Each animal received from one to three treatments during the study period. After the trial, gastric biopsies were obtained from each cheetah annually until death or transfer from the facility to assess disease progression. The trial and follow-up period spanned 10 yr. At onset of the trial, all 32 cheetahs had some degree of gastritis, and 26 cheetahs (81%) were colonized with Helicobacter. Inflammatory lesions worsened regardless of treatment or the presence of Helicobacter. No treatment had a significant effect on inflammatory changes except the lansoprazole/clarithromycin/amoxicillin treatment group, which produced a short-term decrease in inflammation when compared to controls. Prednisone had no effect on gastric inflammation. Overall, 65% of colonized cheetahs were initially cleared of histologic evidence of Helicobacter by treatment, with short-term eradication occurring in 100% of the animals treated with omeprazole/clarithromycin/amoxicillin or tetracycline/metronidazole/Pepto- Bismol for 28 days. Long-term follow-up of treated animals in this study clearly demonstrated that these treatments had little effect on life-long progression of gastritis or on Helicobacter burden in individual cheetahs, although some treatments provided short-term reduction in gastritis and Helicobacter. These results provide evidence that Helicobacter alone is not the cause of gastritis in cheetahs and do not support the use of antibacterial treatments in cheetahs unless significant clinical signs (e.g., frequent vomiting/regurgitation, weight loss) are apparent.

Original languageEnglish (US)
Pages (from-to)401-416
Number of pages16
JournalJournal of Zoo and Wildlife Medicine
Volume36
Issue number3
StatePublished - Sep 2005

Fingerprint

Acinonyx
Acinonyx jubatus
gastritis
Gastritis
Helicobacter
therapeutics
animal
Stomach
stomach
clarithromycin
Therapeutics
lesion
antibiotics
Clarithromycin
amoxicillin
inflammation
Amoxicillin
colonization
Inflammation
disease course

Keywords

  • Acinonyx jubatus
  • Cheetah
  • Gastritis
  • Helicobacter
  • Treatment

ASJC Scopus subject areas

  • Environmental Science(all)
  • Animal Science and Zoology
  • veterinary(all)

Cite this

Efficacy and long-term outcome of gastritis therapy in cheetahs (Acinonyx jubatus). / Citino, Scott B.; Munson, Linda.

In: Journal of Zoo and Wildlife Medicine, Vol. 36, No. 3, 09.2005, p. 401-416.

Research output: Contribution to journalArticle

Citino, Scott B. ; Munson, Linda. / Efficacy and long-term outcome of gastritis therapy in cheetahs (Acinonyx jubatus). In: Journal of Zoo and Wildlife Medicine. 2005 ; Vol. 36, No. 3. pp. 401-416.
@article{13f8e38ae74c4dc9bb310a4bdf47e9da,
title = "Efficacy and long-term outcome of gastritis therapy in cheetahs (Acinonyx jubatus)",
abstract = "A prospective clinical trial evaluating efficacy and long-term outcome of treatments for lymphoplasmacytic gastritis in cheetahs (Acinonyx jubatus) was conducted. The study evaluated efficacy of 11 different antibiotic and antiinflammatory treatment protocols in 32 cheetahs (19 male, 13 female) for reducing gastric inflammation and Helicobacter colonization and monitored the course of disease through histologic grading of gastric biopsies. All cheetahs were biopsied up to 1 wk before treatment and then rebiopsied within 1 mo after treatment. Most animals were reassigned to a second treatment regimen within 6 mo. Each animal received from one to three treatments during the study period. After the trial, gastric biopsies were obtained from each cheetah annually until death or transfer from the facility to assess disease progression. The trial and follow-up period spanned 10 yr. At onset of the trial, all 32 cheetahs had some degree of gastritis, and 26 cheetahs (81{\%}) were colonized with Helicobacter. Inflammatory lesions worsened regardless of treatment or the presence of Helicobacter. No treatment had a significant effect on inflammatory changes except the lansoprazole/clarithromycin/amoxicillin treatment group, which produced a short-term decrease in inflammation when compared to controls. Prednisone had no effect on gastric inflammation. Overall, 65{\%} of colonized cheetahs were initially cleared of histologic evidence of Helicobacter by treatment, with short-term eradication occurring in 100{\%} of the animals treated with omeprazole/clarithromycin/amoxicillin or tetracycline/metronidazole/Pepto- Bismol for 28 days. Long-term follow-up of treated animals in this study clearly demonstrated that these treatments had little effect on life-long progression of gastritis or on Helicobacter burden in individual cheetahs, although some treatments provided short-term reduction in gastritis and Helicobacter. These results provide evidence that Helicobacter alone is not the cause of gastritis in cheetahs and do not support the use of antibacterial treatments in cheetahs unless significant clinical signs (e.g., frequent vomiting/regurgitation, weight loss) are apparent.",
keywords = "Acinonyx jubatus, Cheetah, Gastritis, Helicobacter, Treatment",
author = "Citino, {Scott B.} and Linda Munson",
year = "2005",
month = "9",
language = "English (US)",
volume = "36",
pages = "401--416",
journal = "Journal of Zoo and Wildlife Medicine",
issn = "1042-7260",
publisher = "American Association of Zoo Veterinarians",
number = "3",

}

TY - JOUR

T1 - Efficacy and long-term outcome of gastritis therapy in cheetahs (Acinonyx jubatus)

AU - Citino, Scott B.

AU - Munson, Linda

PY - 2005/9

Y1 - 2005/9

N2 - A prospective clinical trial evaluating efficacy and long-term outcome of treatments for lymphoplasmacytic gastritis in cheetahs (Acinonyx jubatus) was conducted. The study evaluated efficacy of 11 different antibiotic and antiinflammatory treatment protocols in 32 cheetahs (19 male, 13 female) for reducing gastric inflammation and Helicobacter colonization and monitored the course of disease through histologic grading of gastric biopsies. All cheetahs were biopsied up to 1 wk before treatment and then rebiopsied within 1 mo after treatment. Most animals were reassigned to a second treatment regimen within 6 mo. Each animal received from one to three treatments during the study period. After the trial, gastric biopsies were obtained from each cheetah annually until death or transfer from the facility to assess disease progression. The trial and follow-up period spanned 10 yr. At onset of the trial, all 32 cheetahs had some degree of gastritis, and 26 cheetahs (81%) were colonized with Helicobacter. Inflammatory lesions worsened regardless of treatment or the presence of Helicobacter. No treatment had a significant effect on inflammatory changes except the lansoprazole/clarithromycin/amoxicillin treatment group, which produced a short-term decrease in inflammation when compared to controls. Prednisone had no effect on gastric inflammation. Overall, 65% of colonized cheetahs were initially cleared of histologic evidence of Helicobacter by treatment, with short-term eradication occurring in 100% of the animals treated with omeprazole/clarithromycin/amoxicillin or tetracycline/metronidazole/Pepto- Bismol for 28 days. Long-term follow-up of treated animals in this study clearly demonstrated that these treatments had little effect on life-long progression of gastritis or on Helicobacter burden in individual cheetahs, although some treatments provided short-term reduction in gastritis and Helicobacter. These results provide evidence that Helicobacter alone is not the cause of gastritis in cheetahs and do not support the use of antibacterial treatments in cheetahs unless significant clinical signs (e.g., frequent vomiting/regurgitation, weight loss) are apparent.

AB - A prospective clinical trial evaluating efficacy and long-term outcome of treatments for lymphoplasmacytic gastritis in cheetahs (Acinonyx jubatus) was conducted. The study evaluated efficacy of 11 different antibiotic and antiinflammatory treatment protocols in 32 cheetahs (19 male, 13 female) for reducing gastric inflammation and Helicobacter colonization and monitored the course of disease through histologic grading of gastric biopsies. All cheetahs were biopsied up to 1 wk before treatment and then rebiopsied within 1 mo after treatment. Most animals were reassigned to a second treatment regimen within 6 mo. Each animal received from one to three treatments during the study period. After the trial, gastric biopsies were obtained from each cheetah annually until death or transfer from the facility to assess disease progression. The trial and follow-up period spanned 10 yr. At onset of the trial, all 32 cheetahs had some degree of gastritis, and 26 cheetahs (81%) were colonized with Helicobacter. Inflammatory lesions worsened regardless of treatment or the presence of Helicobacter. No treatment had a significant effect on inflammatory changes except the lansoprazole/clarithromycin/amoxicillin treatment group, which produced a short-term decrease in inflammation when compared to controls. Prednisone had no effect on gastric inflammation. Overall, 65% of colonized cheetahs were initially cleared of histologic evidence of Helicobacter by treatment, with short-term eradication occurring in 100% of the animals treated with omeprazole/clarithromycin/amoxicillin or tetracycline/metronidazole/Pepto- Bismol for 28 days. Long-term follow-up of treated animals in this study clearly demonstrated that these treatments had little effect on life-long progression of gastritis or on Helicobacter burden in individual cheetahs, although some treatments provided short-term reduction in gastritis and Helicobacter. These results provide evidence that Helicobacter alone is not the cause of gastritis in cheetahs and do not support the use of antibacterial treatments in cheetahs unless significant clinical signs (e.g., frequent vomiting/regurgitation, weight loss) are apparent.

KW - Acinonyx jubatus

KW - Cheetah

KW - Gastritis

KW - Helicobacter

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=30444434262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444434262&partnerID=8YFLogxK

M3 - Article

C2 - 17312757

AN - SCOPUS:30444434262

VL - 36

SP - 401

EP - 416

JO - Journal of Zoo and Wildlife Medicine

JF - Journal of Zoo and Wildlife Medicine

SN - 1042-7260

IS - 3

ER -